Medtech company chief executive departs with immediate effect
The chief executive of medical technology business Tissue Regenix, Antony Odell, is to leave the company with immediate effect.
He has led the business since 2008 and oversaw its float on the Alternative Investment Market in 2010.
In a statement, the company did not explain the reasons for his departure but said "the integration of CellRight continues as planned and current trading remains in line with board expectations".
The company lost £9.9m in an 11-month financial year, to December 2016, having lost £9.5m in the previ... For the full story register now for free or login below...